Tag: Stereotaxis

Stereotaxis to Initiate First-in-Human Trial to Support CE Mark Application of MAGiC Catheter

ST. LOUIS, June 15, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it intends to initiate a first-in-human trial to support the CE Mark submission for its MAGiC™ catheter. Stereotaxis’ MAGiC catheter is a robotically-navigated […]

Stereotaxis and Abbott Announce Global Collaboration Combining Leading Mapping and Robotic Technologies to Improve Treatment of Abnormal Heart Rhythms

ST. LOUIS, May 19, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS) today announced a global collaboration with Abbott (NYSE: ABT) to integrate Abbott’s EnSite™ X EP System with Stereotaxis’ Robotic Magnetic Navigation systems. The combination of Abbott’s leading cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with […]

Broward Health Medical Center the First Hospital in Florida Using Advanced Genesis Robotic Technology to Treat Heart Rhythm Disorders

ST. LOUIS, March 20, 2023 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the grand opening of a new robotic electrophysiology program at Broward Health Medical Center in Fort Lauderdale, Florida. Broward Health is among the first in the […]

Corewell Health Grows Robotic Program to Treat Heart Rhythm Disorders with Adoption of Stereotaxis’ Genesis System

ST. LOUIS, Dec. 20, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in robotic technologies for the treatment of cardiac arrhythmias, today announced the successful treatment of patients using the latest Genesis Robotic Magnetic Navigation (RMN) system by physicians of the nationally recognized Fred & Lena Meijer Heart […]

Stereotaxis Reports 2022 Third Quarter Financial Results

ST. LOUIS, Nov. 10, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third quarter ended September 30, 2022. “Stereotaxis continues to demonstrate robust commercial and technological progress,” said David Fischel, Chairman and CEO. “We […]

Stereotaxis Receives St. Louis Mayor’s Innovation Award for 2022

ST. LOUIS, Oct. 03, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O. Jones. This recognition reflects Stereotaxis’ regional leadership in […]

Overland Park Regional Medical Center Extends Leadership in Robotic Treatment of Heart Rhythm Disorders with Plans for Second Stereotaxis System

ST. LOUIS, Sept. 13, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the treatment of heart rhythm disorders. OPRMC, a part of HCA Midwest […]

Stereotaxis Reports 2022 Second Quarter Financial Results

ST. LOUIS, Aug. 09, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022. “Despite macro pressures and the poor optics of our financial results, Stereotaxis is making significant progress […]